New Kerendia data show impact of early albuminuria reduction in patients with chronic kidney disease, type 2 diabetes: Bayer

The post hoc mediation analysis used data from the pooled analysis FIDELITY to quantify finerenone-induced kidney and CV risk reductions over a 4-year period, compared to placebo, mediated by change in urine albumin-to-creatinine ratio after 4 months of treatment. To measure the mediated effect of UACR reduction, causal mediation analyses were conducted, separating composite kidney (kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline, or kidney death) and CV outcomes (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure).

The analysis showed that UACR reduction, analyzed as a continuous variable, mediated 83% and 36% of the treatment effect of finerenone on the kidney and CV outcomes, respectively.

“It is good news to see that early UACR reduction with finerenone translates especially into a reduction of kidney complications,” said Dr. Christian Rommel, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Research and Development. “At Bayer, our commitment to improve the long-term outcomes of patients in need of innovative treatments is unwavering. The new findings help underscore the important role finerenone can play in improving the lives of people living with chronic kidney disease associated with type 2 diabetes.”